Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
19 févr. 2021 13h25 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
16 févr. 2021 22h00 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference
10 sept. 2020 08h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering
20 juil. 2020 09h09 HE
|
Daxor Corporation
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology...
AETERNA ZENTARIS ANNOUNCES CLOSING OF $12 MILLION PUBLIC OFFERING
07 juil. 2020 16h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., July 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...
Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
14 mai 2020 13h00 HE
|
Akers Biosciences Inc.
Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
11 mars 2020 09h40 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, March 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market
27 févr. 2020 07h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
11 févr. 2020 16h01 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering
05 déc. 2019 09h25 HE
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the...